Firma TME Pharma, Autor bei PR-Web

TME Pharma reports on end of six-month lock-up period of shares and convertible bonds following the April 2023 transaction

Posted on 18. October 202321. October 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, gloria, market, nox, optimus, patients, radiotherapy, statements, treatment, tumor, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the end of the six-month soft lock-up period of shares and the end of […]

Results of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract

Posted on 3. July 2023 by Firma TME Pharma Posted in General Tagged a12, agm, amf, brain, cancer, clinical, glioblastoma, market, nox, optimus, patients, radiotherapy, securities, statements, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the results of its 2023 annual general meeting of shareholders (AGM), which took place […]

TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma

Posted on 28. June 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, market, methylation, nox, optimus, patients, radiotherapy, statements, strong, vegf, with

83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month mark further surpasses the expected survival in patients resistant to chemotherapy with incomplete surgical tumor removal Survival data will improve further as […]

TME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders

Posted on 30. May 2023 by Firma TME Pharma Posted in General Tagged a12, agm, brain, cancer, clinical, euroclear, glioblastoma, nox, optimus, patients, radiotherapy, report, statements, treatment, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened […]

TME Pharma publishes audited annual report 2022

Posted on 25. April 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, fiscal, glioblastoma, market, nox, optimus, patients, radiotherapy, report, statements, supervisory, with

Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab Survival data continue to improve with 83% of patients alive after one year 15-month […]

TME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program with a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway into December 2023

Posted on 19. April 202320. April 2023 by Firma TME Pharma Posted in General Tagged a12, aso, atlas, brain, cancer, clinical, glioblastoma, market, new, nox, optimus, patients, radiotherapy, statements, with

€2 million new cash secured Termination of the convertible bond agreement by TME Pharma Lock-up of all new shares issued and all outstanding convertible bonds for a period of 6 months to align investors and support company through next clinical […]

TME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022

Posted on 19. April 202320. April 2023 by Firma TME Pharma Posted in General Tagged a12, aso, atlas, brain, cancer, clinical, derivatives, fiscal, nox, optimus, patients, radiotherapy, revenues, statements, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the publication of unaudited financial results for the fiscal year 2022 in order to […]

TME Pharma announces convocation of an extraordinary general meeting of shareholders

Posted on 2. January 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, egm, euroclear, glioblastoma, nox, optimus, patients, radiotherapy, statements, treatment, tumor, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an extraordinary general meeting of shareholders (the EGM) of the company is […]

TME Pharma announces the resignation of its chief financial officer Bryan Jennings

Posted on 29. November 2022 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, market, new, nox, optimus, patients, radiotherapy, statements, treatment, tumor, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company’s Chief Financial Officer (CFO), Bryan Jennings, has resigned for personal […]

TME Pharma reports H1 2022 Financial results and provides business update

Posted on 27. October 2022 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, drugs, new, nox, optimus, patients, radiotherapy, statements, therapy, treatment, vegf, with

Promising top-line results warrant focus of the clinical development on NOX-A12 combination therapies in brain cancer NOX-A12 + bevacizumab 12-month survival data in glioblastoma expected in April 2023 Cash runway into June 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), […]